6-Hydroxybuspirone Is a Major Active Metabolite of Buspirone: Assessment of Pharmacokinetics and 5-Hydroxytryptamine1A Receptor Occupancy in Rats

@article{Wong20076HydroxybuspironeIA,
  title={6-Hydroxybuspirone Is a Major Active Metabolite of Buspirone: Assessment of Pharmacokinetics and 5-Hydroxytryptamine1A Receptor Occupancy in Rats},
  author={Harvey Wong and Randy C. Dockens and Lori Pajor and Suresh N. Yeola and James E Grace and Arlene D. Stark and Rebecca A. Taub and Frank D. Yocca and Robert C. Zaczek and Yu-Wen Li},
  journal={Drug Metabolism and Disposition},
  year={2007},
  volume={35},
  pages={1387 - 1392}
}
The pharmacokinetics and in vivo potency of 6-hydroxybuspirone (6-OH-buspirone), a major metabolite of buspirone, were investigated. The plasma clearance (47.3 ± 3.5 ml/min/kg), volume of distribution (2.6 ± 0.3 l/kg), and half-life (1.2 ± 0.2 h) of 6-OH-buspirone in rats were similar to those for buspirone. Bioavailability was higher for 6-OH-buspirone (19%) compared with that for buspirone (1.4%). After intravenous infusions to steady-state levels in plasma, 6-OH-buspirone and buspirone… 

Figures and Tables from this paper

Inhibition of Axitinib on Buspirone Metabolism in vitro and in vivo

Axitinib inhibited buspir one metabolism in vivo and in vitro, which increases the risk of the side effects of buspirone in the clinic, and when coadministered with axitinib, a lower dosage of busPirone should be defined to avoid a toxic response.

Effects of buspirone on posthypoxic ventilatory behavior in the C57BL/6J and A/J mouse strains.

It is concluded that buspirone improves posthypoxic ventilatory irregularities in the B6 mouse through its agonist effects on the 5-HT1A receptor.

Therapeutic doses of buspirone block D3 receptors in the living primate brain.

For oral buspirone to achieve greater than 80% sustained D3R occupancy, as might be needed to treat addiction, higher doses than those used to treat anxiety (maximal 60 mg) will be required.

Modification of cocaine self-administration by buspirone (buspar 1 ): potential involvement of D 3 and D 4 dopamine receptors

The present research examined both the functional effects of buspirone on these receptors and, in non-human primates, its ability to modify the reinforcing e-maintained behaviour of i.v. cocaine in a behaviourally selective manner to support the further evaluation of busPirone as a candidate medication for the management of cocaine addiction.

Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.

In conscious rats, 5m significantly increased extracellular 5-HT levels in the brain after acute and 3 days of treatment, indicating that 5m is a novel multimodal serotonergic compound, and5m is currently in clinical development for major depressive disorder.

Modification of cocaine self-administration by buspirone (buspar®): potential involvement of D3 and D4 dopamine receptors.

The present research examined the functional effects of buspirone on D3 and D4 receptors and its ability to modify the reinforcing effects of i.v. cocaine in a behaviourally selective manner, supporting the further evaluation of busPirone as a candidate medication for the management of cocaine addiction.

Development of HPLC Method for the Determination of Buspirone in Rat Plasma Using Fluorescence Detection and Its Application to a Pharmacokinetic Study.

A simple and sensitive analytical method for the quantitative determination of buspirone in rat plasma by HPLC with fluorescence detection was developed and validated using naproxen as an internal standard and successfully applied to intravenous and oral pharmacokinetic studies of busPirone in rats.

Characteristics of metabolic stability and the cell permeability of 2‐pyrimidinyl‐piperazinyl‐alkyl derivatives of 1H‐imidazo[2,1‐f]purine‐2,4(3H,8H)‐dione with antidepressant‐ and anxiolytic‐like activities

Molecular modeling studies revealed differences in binding mode between compound 4b and buspirone, which might reflect variation of the ligands’ affinity and potency in the 5‐HT1A receptor.

References

SHOWING 1-10 OF 42 REFERENCES

Pharmacokinetic-Pharmacodynamic Modeling of Buspirone and Its Metabolite 1-(2-Pyrimidinyl)-piperazine in Rats

The results of this analysis show that buspirone and 1- PP behave as partial 5-hydroxytryptamine1A agonists in vivo and that following intravenous administration the amount of 1-PP formed is too small to contribute to the hypothermic effect.

Disposition and metabolism of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in the rat.

The metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) has a longer t1/2 than buspirone and may contribute to the pharmacological effect of the parent drug.

Clinical Pharmacokinetics and Pharmacodynamics of Buspirone, an Anxiolytic Drug

The mechanism of action of the drug is not well characterised, but it may exert its effect by acting on the dopaminergic system in the central nervous system or by binding to serotonin (5-hydroxytryptamine) receptors.

CYTOCHROME P450 3A-MEDIATED METABOLISM OF BUSPIRONE IN HUMAN LIVER MICROSOMES

The metabolism rates of buspirone in CYP2D6 poor-metabolizer genotype HLMs were comparable to those in pooled HLMs, and data suggest that CYP3A, mostly likely CYP 3A4, is primarily responsible for the metabolism of bus Pirone in HLMs.

1-(2-Pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat.

Results, together with the fact that PmP is biochemically and pharmacologically active, suggest that the metabolite may contribute significantly to the central effects of the parent drug.

CYTOCHROME P 450 3 A-MEDIATED METABOLISM OF BUSPIRONE IN HUMAN LIVER MICROSOMES

CYP3A, mostly likely CYP3A4, is primarily responsible for the metabolism of buspirone in HLMs, and it is suggested that urinary excretion is the major elimination pathway in humans, accounting for 60% of the total oral dose of [C]buspirone.

Pharmacokinetics of a Newly Identified Active Metabolite of Buspirone After Administration of Buspirone Over Its Therapeutic Dose Range

Assessment of the pharmacokinetics of a newly identified active metabolite of buspirone, 6‐hydroxybuspirone (6OHB), over the therapeutic dose range ofBuspirone found that 6OHB was rapidly formed following busPirone administration, and exposure increased proportionally with buspir one dose.

Metabolism of the antianxiety drug buspirone in human subjects.

The metabolism of an oral dose of the antianxiety drug buspirone labeled with 14C/15N was studied in human subjects to facilitate structural characterization of the metabolites by mass spectrometry.

Population pharmacokinetic-pharmacodynamic modelling of S 15535, a 5-HT(1A) receptor agonist, using a behavioural model in rats.